Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Annamycin in STS with Pulmonary Metastases
NCT05518526Phase 2Unknown
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in soft tissue sarcoma (STS), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoints: Recommended Phase 2 Dose up to 24 weeks and Progression-Free Survival at 3 months. Status: unknown.
02
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05518526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518526.